Strategies to avoid TAVI-related acute kidney injury

Current Pharmaceutical Design

Volumn 22, Issue 13, 2016, Pages 1950-1958

  Kampaktsis, Polydoros N ^a   Feldman, Dmitriy N ^a   Charitakis, Konstantinos ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute kidney injury; Contrast induced nephropathy; Transcatheter aortic valve implantation

Indexed keywords

ASCORBIC ACID; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BLEEDING; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INCIDENCE; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSFUSION; ACUTE KIDNEY INJURY; ADVERSE EFFECTS;

ACUTE KIDNEY INJURY; HUMANS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84964240996     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151208120522     Document Type: Article

References (106)

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363(17): 1597-607.
2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364(23): 2187-98.
3. Tchetche D, Farah B, Misuraca L, et al. Cerebrovascular events post-transcatheter aortic valve replacement in a large cohort of patients: a FRANCE-2 registry substudy. JACC Cardiovasc Interv 2014; 7(10): 1138-45.
4. Athappan G, Gajulapalli RD, Sengodan P, et al. Influence of transcatheter aortic valve replacement strategy and valve design on stroke after transcatheter aortic valve replacement: a meta-analysis and systematic review of literature. J Am Coll Cardiol 2014; 63(20): 2101-10.
5. Genereux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol 2014; 63(11): 1100-9.
6. Panchal HB, Ladia V, Amin P, et al. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events in patients undergoing transfemoral versus transapical transcatheter aortic valve implantation using edwards valve for severe aortic stenosis. Am J Cardiol 2014; 114(12): 1882-90.
7. Fearon WF, Kodali S, Doshi D, et al. Outcomes after transfemoral transcatheter aortic valve replacement: a comparison of the randomized PARTNER (Placement of AoRTic TraNscathetER Valves) trial with the NRCA (Nonrandomized Continued Access) registry. JACC Cardiovasc Interv 2014; 7(11): 1245-51.
8. Steinvil A, Leshem-Rubinow E, Halkin A, et al. Vascular complications after transcatheter aortic valve implantation and their association with mortality reevaluated by the valve academic research consortium definitions. Am J Cardiol 2015; 115(1): 100-6.
9. Siontis GC, Juni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol 2014; 64(2): 129-40.
10. Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the partner (placement of aortic transcatheter valves) trial and registry. JACC Cardiovasc Interv 2015; 8(1 Pt A): 60-9.
11. Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloonexpandable valve. J Am Coll Cardiol 2012; 60(18): 1743-52.
12. Gargiulo G, Sannino A, Capodanno D, et al. Impact of postoperative acute kidney injury on clinical outcomes after TAVI: A metaanalysis of 5, 971 patients. Catheter Cardiovasc Interv 2015; 86(3): 518-27.
13. Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T, All-Literature investigation of cardiovascular evidence group. Incidence, predictors, and prognosis of acute kidney injury after transcatheter aortic valve implantation: a summary of contemporary studies using Valve Academic Research Consortium definitions. Int J Cardiol 2013; 168(2): 1631-5.
14. Garcia-Lara J, Pinar-Bermudez E, Gimeno-Blanes JR, et al. Incidence, predictors, and effects of acute kidney injury after percutaneous valve implantation. J Invasive Cardiol 2014; 26(4): 183-6.
15. Bagur R, Webb JG, Nietlispach F, et al. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J 2010; 31(7): 865-874.
16. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51(15): 1419-28.
17. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012; 60(15): 1438-54.
18. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 2011; 32(2): 205-17.
19. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure -definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8(4): R204-12.
20. Elhmidi Y, Bleiziffer S, Deutsch MA, et al. Acute kidney injury after transcatheter aortic valve implantation: incidence, predictors and impact on mortality. Arch Cardiovasc Dis 2014; 107(2): 133-9.
21. Aregger F, Wenaweser P, Hellige GJ, et al. Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement. Nephrol Dial Transplant 2009; 24(7): 2175-9.
22. Elhmidi Y, Bleiziffer S, Piazza N, et al. Incidence and predictors of acute kidney injury in patients undergoing transcatheter aortic valve implantation. Am Heart J 2011; 161(4): 735-9.
23. Saia F, Ciuca C, Taglieri N, et al. Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome. Int J Cardiol 2013; 168(2): 1034-40.
24. Barbanti M, Latib A, Sgroi C, et al. Acute kidney injury after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis: results from a large multicentre Italian research project. EuroIntervention 2014; 10(1): 133-40.
25. Genereux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3, 519 patients from 16 studies. J Am Coll Cardiol 2012; 59(25): 2317-26.
26. Konigstein M, Ben-Assa E, Abramowitz Y, et al. Usefulness of updated valve academic research consortium-2 criteria for acute kidney injury following transcatheter aortic valve implantation. Am J Cardiol 2013; 112(11): 1807-11.
27. Shacham Y, Rofe M, Leshem-Rubinow E, et al. Usefulness of urine output criteria for early detection of acute kidney injury after transcatheter aortic valve implantation. Cardiorenal Med 2014; 4(3-4): 155-60.
28. Giordana F, D'Ascenzo F, Nijhoff F, et al. Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation. Am J Cardiol 2014; 114(9): 1447-1455.
29. Goebel N, Baumbach H, Ahad S, et al. Transcatheter aortic valve replacement: does kidney function affect outcome? Ann Thorac Surg 2013; 96(2): 507-12.
30. Voigtlander L, Schewel J, Martin J, et al. Impact of kidney function on mortality after transcatheter valve implantation in patients with severe aortic valvular stenosis. Int J Cardiol 2015; 178: 275-81.
31. Genereux P, Kodali SK, Green P, et al. Incidence and effect of acute kidney injury after transcatheter aortic valve replacement using the new valve academic research consortium criteria. Am J Cardiol 2013; 111(1): 100-5.
32. Konigstein M, Ben-Assa E, Banai S, et al. Periprocedural bleeding, acute kidney injury, and long-term mortality after transcatheter aortic valve implantation. Can J Cardiol 2015; 31(1): 56-62.
33. Strauch JT, Scherner MP, Haldenwang PL, et al. Minimally invasive transapical aortic valve implantation and the risk of acute kidney injury. Ann Thorac Surg 2010; 89(2): 465-70.
34. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103(5): 368-75.
35. Mastoris I, Schoos MM, Dangas GD, Mehran R. Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies. Clin Cardiol 2014; 37(12): 756-64.
36. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990; 39 (Suppl 4): 10-21.
37. Keles T, Ayhan H, Durmaz T, et al. Improvement in renal functions with transcatheter aortic valve implantation. J Geriatr Cardiol 2013; 10(4): 317-322.
38. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52(19): 1527-39.
39. Tsai TT, Patel UD, Chang TI, et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. J Am Heart Assoc 2014; 3(6): e001380.
40. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113(14): 1799-806.
41. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93(12): 1515-9.
42. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105(19): 2259-2264.
43. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98(6A): 27K-36K.
44. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44(7): 1393-9.
45. Dumonteil N, van der Boon RM, Tchetche D, et al. Impact of preoperative chronic kidney disease on short-and long-term outcomes after transcatheter aortic valve implantation: a Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. Am Heart J 2013; 165(5): 752-60.
46. Allende R, Webb JG, Munoz-Garcia AJ, et al. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. Eur Heart J 2014; 35(38): 2685-96.
47. Yamamoto M, Hayashida K, Mouillet G, et al. Prognostic value of chronic kidney disease after transcatheter aortic valve implantation. J Am Coll Cardiol 2013; 62(10): 869-877.
48. Gargiulo G, Capodanno D, Sannino A, et al. Moderate and severe preoperative chronic kidney disease worsen clinical outcomes after transcatheter aortic valve implantation: meta-analysis of 4992 patients. Circ Cardiovasc Interv 2015; 8(2): e002220.
49. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high-and low-osmolality iodinated contrast media. Radiology 1993; 188(1): 171-8.
50. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A metaanalysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48(4): 692-9.
51. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006; 41(11): 815-21.
52. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89(5): 615-20.
53. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86(6 Pt 1): 649-52.
54. Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009; 150(3): 170-7.
55. Brown JR, Robb JF, Block CA, et al. Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? Circ Cardiovasc Interv 2010; 3(4): 346-50.
56. Yamamoto M, Hayashida K, Mouillet G, et al. Renal functionbased contrast dosing predicts acute kidney injury following transcatheter aortic valve implantation. JACC Cardiovasc Interv 2013; 6(5): 479-86.
57. Madershahian N, Scherner M, Liakopoulos O, et al. Renal impairment and transapical aortic valve implantation: impact of contrast medium dose on kidney function and survival. Eur J Cardiothorac Surg 2012; 41(6): 1225-32.
58. Rahnavardi M, Santibanez J, Sian K, Yan TD. A systematic review of transapical aortic valve implantation. Ann Cardiothorac Surg 2012; 1(2): 116-128.
59. Arrigo M, Maisano F, Haueis S, Binder RK, Taramasso M, Nietlispach F. Transcatheter aortic-valve implantation with one single minimal contrast media injection. Catheter Cardiovasc Interv 2014 Dec 24.
60. Pershad A, Fraij G, Girotra SV, Fang HK, Gellert G. TEE-Guided transcatheter aortic valve implantation with "Zero Contrast" -A viable alternative for patients with chronic kidney disease. J Invasive Cardiol 2015; 27(2): E25-6.
61. Jochheim D, Schneider VS, Schwarz F, et al. Contrast-induced acute kidney injury after computed tomography prior to transcatheter aortic valve implantation. Clin Radiol 2014; 69(10): 1034-1038.
62. Azzalini L, Abbara S, Ghoshhajra BB. Ultra-low contrast computed tomographic angiography (CTA) with 20-mL total dose for transcatheter aortic valve implantation (TAVI) planning. J Comput Assist Tomogr 2013 Dec 27.
63. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300(9): 1038-1046.
64. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162(3): 329-36.
65. Lameire N, Kellum JA, KDIGO AKI Guideline Work Group. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care 2013; 17(1): 205.
66. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. Prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol 1999; 33(2): 403-11.
67. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010; 122(23): 2451-5.
68. Briguori C, Visconti G, Focaccio A, et al. Renal insufficiency after contrast media administration trial II (REMEDIAL II): renalguard system in high-risk patients for contrast-induced acute kidney injury. Circulation 2011; 124(11): 1260-9.
69. Marenzi G, Ferrari C, Marana I, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv 2012; 5(1): 90-7.
70. Arbel Y, Ben-Assa E, Halkin A, et al. Forced diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): study protocol for a randomized sham-controlled trial. Trials 2014; 15: 262-15.
71. Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014; 383(9931): 1814-23.
72. Cruz DN, Perazella MA, Bellomo R, et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 2006; 48(3): 361-71.
73. Gabutti L, Marone C, Monti M, et al. Does continuous venovenous hemodiafiltration concomitant with radiological procedures provide a significant and safe removal of the iodinated contrast ioversol? Blood Purif 2003; 21(2): 152-7.
74. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349(14): 1333-40.
75. Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98(6A): 59K-77K.
76. Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol 2008; 21(1): 74-85.
77. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 2014; 63(1): 71-79.
78. Erturk M, Uslu N, Gorgulu S, et al. Does intravenous or oral highdose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C? Coron Artery Dis 2014; 25(2): 111-7.
79. Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115(10): 1211-7.
80. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110(18): 2837-42.
81. Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with metaanalysis of randomized, controlled trials. J Am Coll Cardiol 2013; 62(23): 2167-75.
82. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence? J Am Coll Cardiol 2009; 54(15): 1425-33.
83. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17(7): 2006-16.
84. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008; 51(25): 2375-84.
85. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006; 97(11): 1602-6.
86. Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004; 15(9): 2502-3.
87. McCullough PA, Khambatta S, Jazrawi A. Minimizing the renal toxicity of iodinated contrast. Circulation 2011; 124(11): 1210-1.
88. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010; 55(10): 1002-6.
89. Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012; 126(25): 3008-16.
90. Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104(4): 519-24.
91. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast mediuminduced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. Am Heart J 2008; 155(3): 499.e1-499.e8.
92. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol 2011; 151(3): 348-53.
93. Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010; 105(3): 288-92.
94. Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am J Cardiol 2014; 114(4): 541-8.
95. Bufton KA, Augoustides JG, Cobey FC. Anesthesia for transfemoral aortic valve replacement in North America and Europe. J Cardiothorac Vasc Anesth 2013; 27(1): 46-49.
96. Petronio AS, Giannini C, De Carlo M, et al. Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry. EuroIntervention 2015; 10(11): 10.4244/EIJY15M03_05.
97. Oguri A, Yamamoto M, Mouillet G, et al. Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia: subanalysis of the French Aortic National CoreValve and Edwards 2 registry. Circ Cardiovasc Interv 2014; 7(4): 602-610.
98. Klein AA, Skubas NJ, Ender J. Controversies and complications in the perioperative management of transcatheter aortic valve replacement. Anesth Analg 2014; 119(4): 784-98.
99. Selle A, Figulla HR, Ferrari M, et al. Impact of rapid ventricular pacing during TAVI on microvascular tissue perfusion. Clin Res Cardiol 2014; 103(11): 902-911.
100. Genereux P, Webb JG, Svensson LG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the partner (placement of aortic transcatheter valve) trial. J Am Coll Cardiol 2012; 60(12): 1043-52.
101. Di Mario C, Eltchaninoff H, Moat N, et al. The 2011-12 pilot european sentinel registry of transcatheter aortic valve implantation: inhospital results in 4, 571 patients. EuroIntervention 2013; 8(12): 1362-71.
102. Arai T, Morice MC, O'Connor SA, et al. Impact of pre-and postprocedural anemia on the incidence of acute kidney injury and 1-year mortality in patients undergoing transcatheter aortic valve implantation (from the French Aortic National CoreValve and Edwards 2 [FRANCE 2] Registry). Catheter Cardiovasc Interv 2015 Jan 13.
103. Barbash IM, Ben-Dor I, Dvir D, et al. Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. Am Heart J 2012; 163(6): 1031-6.
104. Nuis RJ, Rodes-Cabau J, Sinning JM, et al. Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2012; 5(5): 680-8.
105. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34(6): 1608-16.
106. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116(22): 2544-52.